Gerard Morton

List of Publications by Year
in descending order

125 papers	3,772 citations	136950 32 h-index	133252 59 g-index
125 all docs	125 docs citations	125 times ranked	3016 citing authors

#	Article	IF	Citations
1	Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the) Tj ETQq1 1 0.784314 rgBT /Overlock aÂLow-Dose-Rate Brachytherapy Boost to aÂDose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 275-285.	0.8	606
2	American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy, 2012, 11, 20-32.	0.5	257
3	ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 286-295.	0.8	250
4	Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer. JAMA Oncology, 2018, 4, e180039.	7.1	238
5	PREVALENCE AND PATTERNS OF THE USE OF COMPLEMENTARY THERAPIES AMONG PROSTATE CANCER PATIENTS: AN EPIDEMIOLOGICAL ANALYSIS. Journal of Urology, 1999, 161, 1521-1524.	0.4	123
6	Target position variability throughout prostate radiotherapy. International Journal of Radiation Oncology Biology Physics, 1998, 42, 1155-1161.	0.8	122
7	Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19ÂGy or two fractions of 13.5ÂGy. Radiotherapy and Oncology, 2020, 146, 90-96.	0.6	92
8	Is single fraction 15Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?. Radiotherapy and Oncology, 2011, 100, 463-467.	0.6	84
9	Long-term outcome of postorchiectomy surveillance for Stage I testicular seminoma. International Journal of Radiation Oncology Biology Physics, 2005, 61, 736-740.	0.8	83
10	Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 418-425.	0.8	77
11	Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy. Radiotherapy and Oncology, 2017, 122, 87-92.	0.6	75
12	Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?. International Journal of Radiation Oncology Biology Physics, 2002, 52, 674-680.	0.8	63
13	(IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. International Journal of Radiation Oncology Biology Physics, 2002, 53, 269-276.	0.8	58
14	Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy. Cancer, 2007, 109, 1506-1512.	4.1	56
15	A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526). International Journal of Radiation Oncology Biology Physics, 2019, 103, 335-343.	0.8	56
16	Long-Term Results of a Phase II Trial of Ultrasound-Guided Radioactive Implantation of the Prostate for Definitive Management of Localized Adenocarcinoma of the Prostate (RTOG 98-05). International Journal of Radiation Oncology Biology Physics, 2011, 81, 1-7.	0.8	54
17	Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2018, 102, 561-567.	0.8	54
18	Pathological Predictors for Site of Local Recurrence After Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e441-e448.	0.8	52

#	Article	IF	Citations
19	Evaluation of a Machine-Learning Algorithm for Treatment Planning in Prostate Low-Dose-Rate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2017, 97, 822-829.	0.8	50
20	ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer.. Journal of Clinical Oncology, 2015, 33, 3-3.	1.6	50
21	High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success. Radiotherapy and Oncology, 2015, 115, 84-89.	0.6	49
22	Fulminant hepatic failure associated with bicalutamide. Urology, 1997, 49, 283-284.	1.0	47
23	Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (Radiation Therapy) Tj ETQq1 1 0.784314 rgBT /Over	0.8	46
24	Hypofractionated Concomitant Intensity-Modulated Radiotherapy Boost for High-Risk Prostate Cancer: Late Toxicity. International Journal of Radiation Oncology Biology Physics, 2012, 82, 898-905.	0.8	46
25	A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 546-555.	0.8	42
26	MR-guided Prostate Biopsy for Planning of Focal Salvage after Radiation Therapy. Radiology, 2015, 274, 181-191.	7.3	40
27	A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: Preliminary results of RTOG P-0019. International Journal of Radiation Oncology Biology Physics, 2006, 64, 804-809.	0.8	37
28	Testosterone Recovery After Prolonged Androgen Suppression in Patients With Prostate Cancer. Journal of Urology, 2008, 180, 1438-1444.	0.4	36
29	Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse. International Journal of Radiation Oncology Biology Physics, 2009, 75, 983-989.	0.8	36
30	Hypofractionated Accelerated Radiotherapy Using Concomitant Intensity-Modulated Radiotherapy Boost Technique for Localized High-Risk Prostate Cancer: Acute Toxicity Results. International Journal of Radiation Oncology Biology Physics, 2008, 72, 85-92.	0.8	34
31	Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19ÂGy high-dose-rate brachytherapy. Brachytherapy, 2018, 17, 291-297.	0.5	34
32	Prospective Assessment of Gastrointestinal and Genitourinary Toxicity of Salvage Radiotherapy for Patients With Prostate-Specific Antigen Relapse or Local Recurrence After Radical Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2008, 72, 792-798.	0.8	32
33	Patient costs associated with external beam radiotherapy treatment for localized prostate cancer: the benefits of hypofractionated over conventionally fractionated radiotherapy. Canadian Journal of Urology, 2012, 19, 6165-9.	0.0	27
34	Comparative study of dosimetry between high-dose-rate and permanent prostate implant brachytherapies in patients with prostate adenocarcinoma. Brachytherapy, 2006, 5, 251-255.	0.5	25
35	Urodynamic changes at 18 months post-therapy in patients treated with external beam radiotherapy for prostate carcinoma. International Journal of Radiation Oncology Biology Physics, 2002, 53, 290-296.	0.8	24
36	MRI-based automated detection of implanted low dose rate (LDR) brachytherapy seeds using quantitative susceptibility mapping (QSM) and unsupervised machine learning (ML). Radiotherapy and Oncology, 2018, 129, 540-547.	0.6	24

#	Article	IF	Citations
37	MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial. Radiotherapy and Oncology, 2019, 141, 144-148.	0.6	24
38	Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function. Supportive Care in Cancer, 2010, 18, 715-722.	2.2	23
39	Conventional vs machine learningâ€“based treatment planning in prostate brachytherapy: Results of a Phase I randomized controlled trial. Brachytherapy, 2020, 19, 470-476.	0.5	23
40	Developing and Evaluating Multimedia Patient Education Tools to Better Prepare Prostate-Cancer Patients for Radiotherapy Treatment (Randomized Study). Journal of Cancer Education, 2018, 33, 551-556.	1.3	22
41	A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer. Advances in Radiation Oncology, 2019, 4, 631-640.	1.2	21
42	Clinical evaluation of an MRI-to-ultrasound deformable image registration algorithm for prostate brachytherapy. Brachytherapy, 2019, 18, 95-102.	0.5	21
43	Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective Trials. International Journal of Radiation Oncology Biology Physics, 2020, 107, 136-142.	0.8	21
44	Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526). International Journal of Radiation Oncology Biology Physics, 2022, 112, 1115-1122.	0.8	21
45	Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy. International Journal of Radiation Oncology Biology Physics, 2006, 65, 78-83.	0.8	20
46	Canadian Prostate Brachytherapy in 2012. Canadian Urological Association Journal, 2013, 7, 51.	0.6	19
47	A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer.. Journal of Clinical Oncology, 2015, 33, 4-4.	1.6	19
48	A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. Brachytherapy, 2006, 5, 239-243.	0.5	18
49	Salvage radiotherapy following biochemical relapse after radical prostatectomy: proceedings of the Genito-Urinary Radiation Oncologists of Canada consensus meeting. Canadian Urological Association Journal, 2013, 2, 500.	0.6	17
50	A comparative study of quality of life in patients with localized prostate cancer treated at a single institution: Stereotactic ablative radiotherapy or external beam+high dose rate brachytherapy boost. Radiotherapy and Oncology, 2014, 113, 404-409.	0.6	17
51	Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery. International Journal of Radiation Oncology Biology Physics, 2005, 62, 719-724.	0.8	16
52	Limited efficacy of salvage radiotherapy for biopsy confirmed or clinically palpable local recurrence of prostate carcinoma after surgery. Radiotherapy and Oncology, 2005, 74, 163-167.	0.6	16
53	Prospective Study Evaluating Postoperative Radiotherapy Plus 2-Year Androgen Suppression for Postâ€“Radical Prostatectomy Patients With Pathologic T3 Disease and/or Positive Surgical Margins. International Journal of Radiation Oncology Biology Physics, 2009, 75, 407-412.	0.8	16
54	Analysis of Gastrointestinal and Genitourinary Morbidity of Postoperative Radiotherapy for Pathologic T3 Disease or Positive Surgical Margins After Radical Prostatectomy Using National Cancer Institute Expanded Common Toxicity Criteria. International Journal of Radiation Oncology Biology Physics, 2008, 72, 989-995.	0.8	15

#	Article	IF	Citations
55	Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in Ontario, Canada. Radiotherapy and Oncology, 2020, 152, 42-48.	0.6	15
56	Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost. Radiotherapy and Oncology, 2021, 154, 29-35.	0.6	15
57	Quality of Life After Hypofractionated Concomitant Intensity-Modulated Radiotherapy Boost for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 617-623.	0.8	14
58	The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer. Brachytherapy, 2015, 14, 309-314.	0.5	14
59	Brachytherapy education and certificationâ€"A Canadian approach. Brachytherapy, 2020, 19, 857-860.	0.5	14
60	Quantitative Ultrasound Spectroscopic Imaging for Characterization of Disease Extent in Prostate Cancer Patients. Translational Oncology, 2015, 8, 25-34.	3.7	13
61	Optimized penile surface mold brachytherapy using latest stereolithography techniques: A single-institution experience. Brachytherapy, 2019, 18, 348-352.	0.5	13
62	Postimplant Dosimetry of Permanent Prostate Brachytherapy: Comparison of MRI-Only and CT-MRI Fusion-Based Workflows. International Journal of Radiation Oncology Biology Physics, 2020, 106, 206-215.	0.8	13
63	The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation. British Journal of Cancer, 2018, 118, 1399-1405.	6.4	12
64	Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial. Radiotherapy and Oncology, 2021, 156, 160-165.	0.6	12
65	Prospective Evaluation of Quality of Life in Prostate Cancer Patients Receiving Combined Treatment of Postoperative Radiotherapy Plus Androgen Suppression for PT3 or Positive Resection Margin after Radical Prostatectomy. European Urology, 2007, 52, 1645-1652.	1.9	11
66	The best method for dose escalation: Prostate brachytherapy. Canadian Urological Association Journal, 2012, 6, 196-198.	0.6	10
67	PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study. Brachytherapy, 2021, 20, 1090-1098.	0.5	10
68	Diagnosis, referral, and primary treatment decisions in newly diagnosed prostate cancer patients in a multidisciplinary diagnostic assessment program. Canadian Urological Association Journal, 2016, 10, 120.	0.6	10
69	High-dose-rate prostate brachytherapy in a patient with bilateral hip prostheses planned using megavoltage computed tomography images acquired with a helical tomotherapy unit. Brachytherapy, 2009, 8, 70-73.	0.5	9
70	Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1066-1073.	0.8	9
71	Sensitivity of clinically relevant dosimetric parameters to contouring uncertainty in postimplant dosimetry of low-dose-rate prostate permanent seed brachytherapy. Brachytherapy, 2016, 15, 774-779.	0.5	8
72	5-Year Outcomes of a Prospective Phase 1/2 Study of Accelerated Hypofractionated Radiation Therapy to the Prostate Bed. Practical Radiation Oncology, 2019, 9, 354-361.	2.1	8

#	Article	IF	Citations
73	Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trials. Radiotherapy and Oncology, 2021, 163, 159-164.	0.6	8
74	Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?. Radiotherapy and Oncology, 2022, 169, 51-56.	0.6	8
75	Feasibility of an MRI-only workflow for postimplant dosimetry of low-dose-rate prostate brachytherapy: Transition from phantoms to patients. Brachytherapy, 2019, 18, 863-874.	0.5	7
76	Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging. Advances in Radiation Oncology, 2021, 6, 100553.	1.2	7
77	Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial. Radiotherapy and Oncology, 2021, 163, 21-31.	0.6	7
78	Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI. Clinical and Translational Radiation Oncology, 2022, 32, 41-47.	1.7	7
79	Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life. Radiotherapy and Oncology, 2021, 161, 40-46.	0.6	6
80	Contemporary management of prostate cancer: a practice survey of Ontario genitourinary radiation oncologists. Radiotherapy and Oncology, 2003, 69, 63-72.	0.6	5
81	Radiation treatment of bladder squamous cell carcinoma in a patient with spina bifida: A case report. Canadian Urological Association Journal, 2012, 6, E125-E128.	0.6	5
82	Changes in ADC and T2-weighted MRI-derived radiomic features in patients treated with focal salvage HDR prostate brachytherapy for local recurrence after previous external-beam radiotherapy. Brachytherapy, 2019, 18, 567-573.	0.5	5
83	Estimating acute urinary retention risk post prostate high dose-rate (HDR) brachytherapy: A clinical-based recursive partitioning analysis. Radiotherapy and Oncology, 2021, 154, 118-122.	0.6	5
84	Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol. Brachytherapy, 2006, 5, 152-156.	0.5	4
85	Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer. Radiation Oncology, 2015, 10, 95.	2.7	4
86	Evaluation of an Automated Deformable Registration Algorithm for MRI-Guided Focal Boost Integrated with Ultrasound-Based High-Dose Rate Brachytherapy in the Treatment of Prostate Cancer. Brachytherapy, 2016, 15, S36-S37.	0.5	4
87	Adjuvant Versus Salvage Radiotherapy for Patients With Adverse Pathological Findings Following Radical Prostatectomy: A Decision Analysis. MDM Policy and Practice, 2017, 2, 238146831770947.	0.9	4
88	Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis. Radiotherapy and Oncology, 2020, 150, 195-200.	0.6	4
89	Radiation Oncologist Consultations Prior to Radical Prostatectomy: Disparities and Opportunities. Journal of Urology, 2022, 207, 118-126.	0.4	4
90	Quality of life (QOL) and acute toxicities of a pilot study of focal salvage high-dose rate (HDR) prostate brachytherapy in patients with local recurrence after definitive external-beam radiotherapy (XRT).. Journal of Clinical Oncology, 2015, 33, 79-79.	1.6	4

#	Article	IF	Citations
91	Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy Boost. International Journal of Radiation Oncology Biology Physics, 2022, 112, 735-743.	0.8	4
92	Role of radiotherapy in the treatment of cancer of the ovary. Journal of Surgical Oncology, 1994, 10, 305-312.	1.4	3
93	A prospective study on pain score with transperineal prostatic gold seed fiducial implantation under local anesthetic alone. Canadian Urological Association Journal, 2013, 7, e202-6.	0.6	3
94	Dosimetric impact of inter-observer catheter reconstruction variability in ultrasound-based high-dose-rate prostate brachytherapy. Brachytherapy, 2018, 17, 306-312.	0.5	3
95	Efficacy Results of a Randomized Trial of Prostate HDR Monotherapy in Either One or Two Fractions for Low and Intermediate Risk Disease. Brachytherapy, 2019, 18, S52-S53.	0.5	3
96	Dosimetric evaluation of MRI-to-ultrasound automated image registration algorithms for prostate brachytherapy. Brachytherapy, 2020, 19, 599-606.	0.5	3
97	Multipurpose ultrasound-based prostate phantom for use in interstitial brachytherapy. Brachytherapy, 2021, 20, 1139-1145.	0.5	3
98	The American Brachytherapy Society and the American Radium Society Appropriate Use Criteria Genitourinary Committee Endorse the American Society of Clinical Oncology/Cancer Care Ontario Guidelines. Journal of Clinical Oncology, 2018, 36, 3342-3344.	1.6	2
99	Radiation Oncology Fellowship: a Value-Based Assessment Among Graduates of a Mature Program. Journal of Cancer Education, 2020, 36, 1295-1305.	1.3	2
100	Low dose rate brachytherapy vs standard external beam radiotherapy vs stereotactic body radiotherapy for low risk prostate cancer: A cost-utility analysis.. Journal of Clinical Oncology, 2016, 34, 6628-6628.	1.6	2
101	Single fraction radiotherapy versus multiple fraction radiotherapy for bone metastases in prostate cancer patients: comparative effectiveness. Cancer Management and Research, 2014, 6, 451.	1.9	1
102	Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians. Canadian Urological Association Journal, 2017, 12, E59-63.	0.6	1
103	Is prostate brachytherapy a dying art? Evidence of increasing utilization in Ontario, Canada.. Journal of Clinical Oncology, 2020, 38, e17608-e17608.	1.6	1
104	Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, survival, and late toxicity outcomes.. Journal of Clinical Oncology, 2020, 38, 328-328.	1.6	1
105	A prospective study on pain score with transperineal prostatic gold seed fiducial implantation under local anesthetic alone. Canadian Urological Association Journal, 2013, 7, 1-5.	0.6	1
106	Biochemical, pathologic, toxicity, and quality-of-life outcomes in a five-fraction hypofractionated accelerated radiotherapy treatment using standard linear accelerators and gold seed fiducials.. Journal of Clinical Oncology, 2012, 30, 186-186.	1.6	1
107	Stereotactic radiotherapy +/- HDR boost for unfavorable-risk prostate cancer: Comparison of efficacy, survival, and late toxicity outcomes.. Journal of Clinical Oncology, 2020, 38, 372-372.	1.6	1
108	A comparative study of patient-reported outcomes after contemporary radiation techniques for prostate cancer. Radiotherapy and Oncology, 2022, 171, 164-172.	0.6	1

#	Article	IF	Citations
109	The best method for dose escalation: Prostate brachytherapy. Canadian Urological Association Journal, 2013, 6, 196-8.	0.6	0
110	Radiation oncologist consultations prior to prostatectomy in Ontario, Canada: Disparities and opportunities.. Journal of Clinical Oncology, 2021, 39, e17052-e17052.	1.6	0
111	High Dose Rate Prostate Brachytherapy. Practical Guides in Radiation Oncology, 2021, , 127-151.	0.1	0
112	Comparison of acute toxicity in patients treated with a 4-field box or IMRT to deliver elective pelvic nodal irradiation for localized high-risk prostate cancer.. Journal of Clinical Oncology, 2012, 30, 69-69.	1.6	0
113	Three-dimensional ultrasound-based spectroscopic imaging for the detection of prostate cancer.. Journal of Clinical Oncology, 2012, 30, 234-234.	1.6	0
114	How does stereotactic body radiotherapy compare to standard external beam radiotherapy or low-dose rate brachytherapy for low-risk prostate cancer?. Journal of Clinical Oncology, 2013, 31, e16070-e16070.	1.6	0
115	Pilot study of focal salvage high-dose rate (HDR) prostate brachytherapy in patients with local recurrence after definitive external-beam radiotherapy (XRT).. Journal of Clinical Oncology, 2014, 32, 264-264.	1.6	0
116	Comparison of active surveillance with other treatment options for low-risk prostate cancer.. Journal of Clinical Oncology, 2015, 33, 178-178.	1.6	0
117	Early toxicity in a randomized trial of high dose-rate (HDR) brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 44-44.	1.6	0
118	MRI response to focal salvage HDR prostate brachytherapy for locally recurrent prostate cancer after external-beam radiotherapy.. Journal of Clinical Oncology, 2016, 34, e631-e631.	1.6	0
119	Three year results of a prospective study on focal salvage HDR prostate brachytherapy for local recurrence after external beam radiotherapy (XRT).. Journal of Clinical Oncology, 2017, 35, e558-e558.	1.6	0
120	Early toxicity in a prospective phase I/II trial of MRI-assisted focal boost integrated with HDR monotherapy for low- and intermediate-risk prostate cancer.. Journal of Clinical Oncology, 2017, 35, 120-120.	1.6	0
121	Hypofractionated, accelerated radiotherapy to the prostate bed: Five-year outcomes of a prospective phase I/II study.. Journal of Clinical Oncology, 2019, 37, 7-7.	1.6	0
122	Evaluating the tolerability of a simultaneous focal boost to the gross tumor in prostate SABR: A toxicity and quality-of-life comparison of two prospective trials.. Journal of Clinical Oncology, 2020, 38, 319-319.	1.6	0
123	Metastatic progression following multimodal therapy for unfavorable-risk prostate cancer. Canadian Urological Association Journal, 2021, 16, .	0.6	0
124	Success of targeted transperineal biopsy in patients on surveillance for grade group 1 prostate cancer. Canadian Urological Association Journal, 2022, 16, .	0.6	0
125	Can a FLAME forge a stronger SABRe? Letâ€™s await the evidence for focal boost with Stereotactic Ablative Radiotherapy. Radiotherapy and Oncology, 2022, , .	0.6	0